EUDA Health Expands into T-Cell Immunotherapy with New Malaysian Partnership

EUDA Health Holdings ( (EUDA) ) just unveiled an update.

On September 4, 2025, EUDA Health Holdings Limited announced its strategic expansion into T-cell immunotherapy by securing distribution rights for these therapies in Malaysia, developed by Shenzhen Inno Immune Co. Ltd. This move marks EUDA’s second major step into advanced cell therapy this year, following a previous partnership in April 2025. The expansion is part of EUDA’s accelerated push into regenerative and longevity medicine, aiming to provide innovative, non-invasive solutions for aging and chronic conditions. The T-cell immunotherapy package will be priced at USD 8,000 per treatment, making it more accessible by addressing cost barriers. This strategic partnership is expected to enhance EUDA’s healthcare portfolio and create significant growth potential in the region.

The most recent analyst rating on (EUDA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on EUDA Health Holdings stock, see the EUDA Stock Forecast page.

More about EUDA Health Holdings

EUDA Health Holdings Limited is a Singapore-based leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China. The company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. EUDA addresses the evolving healthcare needs of over 1.8 billion people across the region, which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. The company also operates a property management business in Singapore.

Average Trading Volume: 92,821

Technical Sentiment Signal: Sell

Current Market Cap: $69.11M

Find detailed analytics on EUDA stock on TipRanks’ Stock Analysis page.